Clinical Trial Update: Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating utidelone (UTD1) in combination with capecitabine for triple-negative breast cancer patients who did not achieve a pathologic complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Utidelone (utidelone)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Triple Negative Breast Neoplasms | Phase 2 | Status: RECRUITING